Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous FormulationMasaaki Yoshikawa, Haruki Koike, Makoto Eriguchi et al.|Neurology and Therapy|2025Cited by 13
Efgartigimod Successfully Ameliorated Acute Exacerbation of Myasthenia Gravis with Anti-muscle-specific Kinase AntibodiesKoya Tanaka, Haruki Koike, Masaaki Yoshikawa et al.|Internal Medicine|2024Cited by 4
The Japanese Version of 26‐Item Informant Questionnaire on Cognitive Decline in the Elderly: Development and Validation StudyMegumi Mizoguchi, Haruki Koike, Shuhei Ikeda et al.|Geriatrics and gerontology international/Geriatrics & gerontology international|2026Cited by 2
Hereditary Neuropathy with Liability to Pressure Palsies Unmasked by Polatuzumab Vedotin-containing ChemotherapyTakeru Kawanami, Haruki Koike, Masaaki Yoshikawa et al.|Internal Medicine|2025Cited by 1